enoxaparin/tinzaparin/dalteparin — Competitive Intelligence Brief

enoxaparin/tinzaparin/dalteparin (enoxaparin/tinzaparin/dalteparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Factor IIa Cardiovascular Small molecule

Target snapshot

enoxaparin/tinzaparin/dalteparin (enoxaparin/tinzaparin/dalteparin) — Helsinki University Central Hospital. Low-molecular-weight heparins that inhibit blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
enoxaparin/tinzaparin/dalteparin TARGET	enoxaparin/tinzaparin/dalteparin	Helsinki University Central Hospital	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Factor IIa
Enoxaparin Injectable Solution	Enoxaparin Injectable Solution	Medical University of Vienna	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Coagulation factors Xa and IIa
dose adaptation of Enoxaparin	dose adaptation of Enoxaparin	French Cardiology Society	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)
Fixed low dose tinzaparin	Fixed low dose tinzaparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Coagulation factors Xa and IIa
Dosing of enoxaparin for VTE prophylaxis	Dosing of enoxaparin for VTE prophylaxis	Intermountain Health Care, Inc.	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)
Low dose nadroparin	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
Hepalean Heparin	Hepalean Heparin	McMaster University	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Factors Xa and IIa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
2. University of Melbourne · 3 drugs in this class
3. French Cardiology Society · 2 drugs in this class
4. Ottawa Hospital Research Institute · 2 drugs in this class
5. McMaster University · 2 drugs in this class
6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
7. GlaxoSmithKline · 1 drug in this class
8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
10. Helsinki University Central Hospital · 1 drug in this class